Table 1.
Current CAR NK cell products.
| Cell Source | Target | Generation | Activation Signal | Transduction | Model | Malignancy | Ref. |
|---|---|---|---|---|---|---|---|
| NK-92 | FLT3 | Second | CD28-CD3ζ | LV | B-ALL CDX model in NOD-SCID IL2R γnull mice | B-ALL | [22] |
| NK-92 | CD38 | Third | CD28-4-1BB-CD3ζ | RV | None | MM, BL |
[135] |
| KHYG1, PB-NK |
CD38 | Second | CD28-CD3ζ | Electroporation | None | AML | [140] |
| NK-92 | CD5 | Second | 4-1BB-CD3ζ, 2B4-CD3ζ |
LV | CD5+T-ALL CDX model in NSG mice | T-ALL | [137] |
| NK-92MI | CD7 | Third | CD28-4-1BB-CD3ζ | Electroporation | T-ALL PDX model in NSG mice | T-ALL | [96] |
| PB-NK | CD33 | Second | 4-1BB-CD3ζ | LV | AML CDX model in NSG mice | AML | [141] |
| NK-92 | CD123 | Third | CD28-4-1BB-CD3ζ | RV | AML PDX model in NSG mice | AML | [142] |
| PB-NK | CD123 | Second | 2B4-CD3ζ | RV | AML CDX model in NSG mice | AML | [143] |
| PB-NK | CD19, SDF-1 |
Second | 4-1BB-CD3ζ | LV | None | B-cell malignancies | [144] |
| CB-NK | CD19 | Second | CD28-CD3ζ | RV | BL CDX model in NSG mice | CD19+leukemia/lymphoma | [145] |
| CB-NK | CD19 | Second | CD28-CD3ζ | RV | BL CDX model in NSG mice | CD19+leukemia/lymphoma | [131] |
| PB-NK | NKG2DL | Third | CD28-4-1BB-CD3ζ | Electroporation | AML CDX model in NSG mice | AML | [146] |
| NK-92 | CD25 | Third | CD28-4-1BB-CD3ζ | LV | None | CD25+T-ALL | [147] |
| NK-92, PB-NK |
GPC3 | Second | CD28-CD3ζ | LV | HCC orthotopic CDX model in NOD/SCID mice | HCC | [148] |
| NK-92 | GPC3 | Third | DNAM1-2B4-CD3ζ | LV | None | HCC | [138] |
| iPSC-NK | GPC3 | Third | CD28-4-1BB-CD3ζ | LV | GPC3+OC CDX model in NSG/NOG mice | OC | [149] |
| NK-92 | αFR | Three | CD3ζ, CD28-CD3ζ, CD28-CD137-CD3ζ |
LV | OC CDX model in B-NDG mice | OC | [150] |
| NK-92 | MSLN | Third | CD28-4-1BB-CD3ζ | LV | OC CDX model in NSG mice | OC | [151] |
| NK-92 | MSLN | Second | 2B4-CD3ζ | LV | GC CDX and PDX model in NSG mice | GC | [152] |
| NK-92MI | TF | Third | CD28-4-1BB-CD3ζ | LV | TNBC CDX and PDX model in NSG mice | TNBC | [153] |
| PB-NK | EGFR | Third | CD28-4-1BB-CD3ζ | LV | TNBC CDX and PDX model in female nude mice | TNBC | [154] |
| PB-NK | NKG2DL | First | DAP-12 | Electroporation | CRC CDX model in NSG mice; Three patients with chemotherapy-refractory metastatic CRC | CRC | [155] |
| PB-NK | NKG2DL | Second | 4-1BB-CD3ζ | LV | MM CDX model in NSG mice | MM | [156] |
| PB-NK | NKG2DL, IL-8 |
First | CD3ζ | Electroporation | OC and HNC CDX model in NSG mice | OC, HNC |
[157] |
| PB-NK | HER2 | Second | CD28-CD3ζ | LV | None | BC | [158] |
| NK-92 | PDL1 | First | 4-1BB | LV | Lung cancer CDX model in NOG mice | Lung cancer | [136] |
| NK-92MI | B7-H3 | Second | 4-1BB-CD3ζ | LV | NSCLC CDX model in NOD/SCID mice | NSCLC | [125] |
| NK-92 | B7-H3 | Second | CD28-CD3ζ | LV | None | Melanoma | [118] |
| PB-NK | HLA-G | First | DAP-12 | LV | MDA-MB-231 and U87 orthotopic xenograft model in NSG mice | Solid tumors | [159] |
| NK-92MI | PD-L1 | Second | CD28-CD3ζ | LV, Electroporation |
BC CDX model in female WT Balb/c, C57BL/6, and NSG mice | BC | [160] |
PB, peripheral blood; CB, cord blood; iPSC, induced pluripotent stem cell; LV, lentivirus; RV, retrovirus; CDX, cell-derived xenograft; PDX, patient-derived xenograft; ILC, Innate lymphoid cells; B-ALL, B-cell acute lymphoblastic leukemia; MM, multiple myeloma; BL, Burkitt’s lymphoma; AML, acute myeloid leukemia; T-ALL, T cell acute lymphoblastic leukemia; HCC, hepatocellular carcinoma; OC, ovarian cancer; HNC, head and neck cancer; BC, breast cancer; GC, gastric cancer; TNBC, triple-negative breast cancer; CRC, colorectal cancer; NSCLC, non-small cell lung cancer.